An antibody against traf2 and Nck-interacting kinase (TNIK), a serine-threonine kinase targeted for cancer therapeutics.
Catalogue number crb2005763 Antibody Anti-TNIK antibody Antigen Peptide KLH conjugated synthetic peptide crb1200972 Protein ID UniProtKB - Q9UKE5 (Human), P83510 (Mouse) Aliases TRAF2 and NCK-interacting protein kinase Cross-Reactivity Human, Mouse Host Species Rabbit Antibody Type Polyclonal Concentration 2.0 mg/ml Glycine Target TRAF2 and NCK-interacting protein kinase Family STE Ser/Thr protein kinase family Super Family Protein kinase superfamily Storage This material is supplied in PBS containing 0.01% sodium azide and 1% trehalose. The product should be stored at +4°C for short term storage and -20°C for long term storage. Avoid repeated freeze/thaw cycles. References
Anazi et al., (2016). A null mutation in TNIK defines a novel locus for intellectual disability. Hum Genet., 135(7): 773. doi: 10.1007/s00439-016-1671-9.
Avais et al., (2022). The serine/threonine kinase MINK1 directly regulates the function of promigratory proteins. J Cell Sci, 135(17): jcs259347. doi: https://doi.org/10.1242/jcs.259347.
Zhou et al., (2023). Inhibition of Wnt Signaling in Colon Cancer Cells via an Oral Drug that Facilitates TNIK Degradation. Mol Cancer Ther, 22(1): 25. doi: 10.1158/1535-7163.MCT-21-0801.
Serine/threonine kinase is an essential activator of the Wnt signalling pathway. Recruited to promoters of Wnt target genes and required to activate their expression. It may act by phosphorylating TCF4/TCF7L2. It appears to work upstream of the JUN N-terminal pathway. Expression of TNIK is highly controlled and enriched in the hypothalamus and cortex. TNIK is part of a signalling complex composed of NEDD4 and RAP2A, which regulates neuronal dendrite extension during development.
Intellectual developmental disorder, autosomal recessive 54 (MRT54), is a disease caused by variants in MINK1. MRT54 disorder manifests as intellectual disability, delayed speech, and hyperactivity.
Inhibitors or targeted degradation of TNIK are both routes explored for therapeutics against lung squamous cell carcinoma, synovial carcinoma, and colon cancer.
We also have antibodies to the TNIK paralog, MINK1.